SCHEMBL13509564

SCHEMBL13509564

Cc1cccc2c1oc1cncnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 6/20 0.38
HPGD P15428 4/20 0.38
LIMK1 P53667 1/20 0.37
MCL1 Q07820 1/20 0.37
PPARG P37231 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CASP3 P42574 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
LMNA P02545 2/20 0.35
RXFP1 Q9HBX9 2/20 0.35
HTT P42858 1/20 0.35
ELANE P08246 1/20 0.35
CYP17A1 P05093 1/20 0.35
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21398140 0.81 SMN1; SMN2 (0.38) SMN1; SMN2MAPTALDH1A1HPGDLIMK1
SCHEMBL72743 0.80 MAOA (0.49) SMN1; SMN2MAPTALDH1A1HPGDNPC1
SCHEMBL25662762 0.77 CYP1A2 (0.35) MAPTALDH1A1HPGDKDM4ELMNA
SCHEMBL13509566 0.77 L3MBTL1 (0.46) SMN1; SMN2MAPTALDH1A1HPGDMCL1
SCHEMBL30356598 0.76 CYP1A2 (0.42) SMN1; SMN2MAPTALDH1A1HPGDLIMK1
SCHEMBL22483141 0.76 CYP1A2 (0.42) SMN1; SMN2MAPTALDH1A1HPGDLIMK1
SCHEMBL25662760 0.75 MCL1 (0.38) SMN1; SMN2MAPTALDH1A1HPGDMCL1
SCHEMBL483929 0.74 SMN1; SMN2 (0.51) SMN1; SMN2MAPTALDH1A1HPGDLIMK1
SCHEMBL19039382 0.73 SMN1; SMN2 (0.40) SMN1; SMN2MAPTALDH1A1HPGDLIMK1
SCHEMBL13509565 0.73 TDO2 (0.40) MCL1CYP17A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230172057-A1 HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) 2023-06-01 US disclosed
US-10040794-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2018-08-07 US disclosed
US-20170186977-A1 Organic Electroluminescent Materials and Devices UNIVERSAL DISPLAY CORPORATION 2017-06-29 US disclosed
US-9314468-B2 Chemokine receptor modulators ALTIRIS THERAPEUTICS, INC. (US) 2016-04-19 US disclosed
US-20130172330-A1 Chemokine Receptor Modulators ALTIRIS THERAPEUTICS, INC. (US) 2013-07-04 US disclosed
US-8338448-B2 Chemokine receptor modulators ALTIRIS THERAPEUTICS, INC. (US) 2012-12-25 US disclosed
US-20100029634-A1 Chemokine Receptor Modulators ALTIRIS THERAPEUTICS, INC. 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230172057-A1 HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE CHRM1, CHRM2, CHRM4 SMN1; SMN2 3262/4885MAPT 4606/4885ALDH1A1 3072/4885
US-20130172330-A1 Chemokine Receptor Modulators CCR5, CXCR4, ACKR3 SMN1; SMN2 4379/4885MAPT 1019/4885ALDH1A1 2030/4885
US-10040794-B2 Condensed cyclic compound and organic light-emitting device including the same CRY1, CCNE2, CRY2 SMN1; SMN2 4546/4885MAPT 1482/4885ALDH1A1 352/4885
US-20170186977-A1 Organic Electroluminescent Materials and Devices KYNU, EML4, INMT SMN1; SMN2 4719/4885MAPT 549/4885ALDH1A1 1063/4885
US-20100029634-A1 Chemokine Receptor Modulators CCR5, CXCR4, ACKR3 SMN1; SMN2 4379/4885MAPT 1019/4885ALDH1A1 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.